Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
BPI CRISPR/Cas9 KO Plasmid (h): sc-404909
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- BPI CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the BPI genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: BPI Antibody (H-10): sc-514212
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
BPI CRISPR/Cas9 KO Plasmid (h) | sc-404909 | 20 µg | $397.00 |
Overview
BPI (bactericidal/permeability-increasing protein) is a neutrophil granule and mucosal innate immunity factor with high affinity for lipopolysaccharide (LPS) on Gram-negative bacteria, where it neutralizes endotoxin activity and promotes bacterial killing by disrupting outer membrane integrity. By binding LPS and modulating interactions with LPS-binding protein and CD14/TLR4 signaling components, BPI can influence downstream inflammatory responses and cytokine production. BPI expression and activity are commonly evaluated in the context of host–pathogen interactions, neutrophil degranulation, and barrier defense. Dysregulated LPS handling and altered BPI levels have been investigated in inflammatory airway and gastrointestinal conditions, sepsis biology, and susceptibility to Gram-negative infections.
BPI CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the BPI gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the BPI together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the BPI open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish BPI protein expression.
This CRISPR knockout system enables efficient generation of BPI-deficient cell models for investigation of BPI signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting BPI exon(s) critical for BPI function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple BPI genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by BPI CRISPR/Cas9 KO Plasmid (h) and BPI CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the BPI locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by BPI HDR Plasmid (h) and BPI HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by BPI homology arms to support homology-directed repair at defined BPI target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.